Author:
Chenot Jean-François,Schmiemann Guido
Reference9 articles.
1. Dathe K, Schaefer C. Drug safety in pregnancy: The German Embryotox institute. Eur J Clin Pharmacol 2018; 74: 171–179.
2. Dubrall D, Schmid M, Alešik E, et al. Frequent adverse drug reactions, and medication groups under suspicion – a descriptive analysis based on spontaneous reports to the German Federal Institute for Drugs and Medical Devices from 1978–2016. Dtsch Arztebl Int 2018; 115: 393–400.
3. Rottenkolber D, Schmiedl S, Rottenkolber M, et al. Adverse drug reactions in Germany: Direct costs of internal medicine hospitalizations. Pharmacoepidemiol Drug Saf 2011; 20: 626–634.
4. Schwabe U, Paffrath D, Ludwig WD, Klauber J. Arzneiverordnungs-Report 2017. Berlin: Springer 2017.
5. Stammschulte T, Weersink R, Suerbruch T, et al. Niederländische Empfehlungen zur sicheren Anwendung von Arzneimitteln bei Leberzirrhose. Arzneiverordnung in der Praxis 2020; www.akdae.de/Arzneimitteltherapie/AVP/vorab/20200127-Leberzirrhose.pdf (letzter Zugriff: 16.7.2021).